Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02419287
Recruitment Status : Active, not recruiting
First Posted : April 17, 2015
Last Update Posted : April 18, 2022
Information provided by (Responsible Party):
University of Milano Bicocca

Brief Summary:
The purpose of this study is to determine the response and the duration of it in patients affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment that will be treated with crizotinib.

Condition or disease Intervention/treatment Phase
Anaplastic Large Cell Lymphoma, ALK-Positive Drug: crizotinib Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
Actual Study Start Date : April 2015
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Crizotinib

Arm Intervention/treatment
Experimental: crizotinib
250mg BID
Drug: crizotinib

Primary Outcome Measures :
  1. objective response rates (ORR) in subjects with ALK+ lymphomas resistant or refractory to standard cytotoxic treatment, according to RECIST 1.1 criteria. [ Time Frame: the entire duration of the study (5 years) ]
  2. Duration ORR [ Time Frame: the entire duration of the study (5 years) ]

Secondary Outcome Measures :
  1. Progression free survival (PFS) in ALK+ lymphoma patients treated with crizotinib, that are resistant or refractory to standard cytotoxic treatment. [ Time Frame: the entire duration of the study (5 years) ]
  2. Number of patients with adverse events after crizotinib treatment [ Time Frame: the entire duration of the study (5 years) ]
  3. Quality of Life (QoL) in this population of patients using the the EORTC - C30 Quality of Life questionnaire [ Time Frame: the entire duration of the study (5 years) ]
  4. Overall survival (OS) in ALK+ lymphoma patients treated with crizotinib [ Time Frame: the entire duration of the study (5 years) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed and dated Informed Consent approved by Local Ethical Committee before any protocol-specific screening procedures.
  2. ALK+ Non-Hodgkin lymphoma diagnosed by IHC or FISH.
  3. Refractory disease or relapse after at least one prior chemotherapy regimen (typically a minimum of 6 cycles of CHOP); presence of measurable disease by physical examination, CT or CT-PET scan.
  4. Any prior chemotherapy or major surgeries must have been completed at least 14 days prior to initiation of study medication. This could not be respected if there is clear evidence of disease progression, manifested as growing pain attributable to the tumour, fever, growing tumour lesions, increasing LDH values.
  5. Able to take oral therapy.
  6. Female or male, 18 years of age or older.
  7. ECOG performance status 0-3.
  8. Adequate organ function as defined by the following criteria:

    • Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN) or AST and ALT ≤ 5 x ULN if liver function abnormalities are due to underlying malignancy
    • Total serum bilirubin 1.5 x ULN (except patients with documented Gilbert's syndrome
    • Creatinine ≤ 1.5 x ULN.
  9. Adequate bone marrow function:

    • Absolute neutrophil count (ANC) ≥ 1000/µL
    • Platelets ≥ 50.000/µL
    • Hemoglobin ≥ 9.0 g/dL The hematological values will not be considered in case of bone marrow involvement.
  10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
  11. Female and male patients who are of childbearing potential must agree to use an effective form of contraception with their partners throughout participation in this study.

Exclusion Criteria:

  1. Current treatment on another therapeutic clinical trial.
  2. Prior therapy specifically directed against ALK.
  3. Major surgery within 14 days prior first dose of crizotinib.
  4. History of uncontrolled cardiac disease including: myocardial infarct, uncontrolled angina or hypertension, clinically significant ventricular arrhythmia, unexplained syncope.
  5. Pregnancy or breastfeeding.
  6. Use of drugs or foods that are known potent CYP3A4 inhibitors, including but not limited to amprenavir, atazanavir, clarithromycin, delavirdine, diltiazem, erythromycin, indinavir, itraconazole, ketoconazole, miconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, verapamil, voriconazole, and grapefruit or grapefruit juice.
  7. Use of drugs that are known potent CYP3A4 inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, tipranavir, ritonavir, and St. John's wort.
  8. Use of drugs that are CYP3A4 substrates with narrow therapeutic indices, including but not limited aripiprazole, ergotamine, halofantrine, pimozide, triazolam, astemizole*, cisapride*, and terfenadine* (* withdrawn from U.S. market).
  9. Prior malignancy other than basal cell carcinoma.
  10. Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02419287

Layout table for location information
Monza, Italy/MB, Italy, 20900
Sponsors and Collaborators
University of Milano Bicocca
Layout table for investigator information
Principal Investigator: Carlo Gambacorti Passerini, MD University of Milano Bicocca
Layout table for additonal information
Responsible Party: University of Milano Bicocca Identifier: NCT02419287    
Other Study ID Numbers: CRU1
First Posted: April 17, 2015    Key Record Dates
Last Update Posted: April 18, 2022
Last Verified: April 2022
Keywords provided by University of Milano Bicocca:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Large-Cell, Anaplastic
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, T-Cell
Lymphoma, Non-Hodgkin
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action